Impact on Medical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients: An Observational Cohort Study Based on SEER-Medicare

Rituximab improves survival in follicular lymphoma (FL), but is considerably more expensive than conventional chemotherapy. We estimated the total direct medical costs, cumulative survival, and cost-effectiveness of adding rituximab to first-line chemotherapy for FL, based on a single source of data...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Griffiths, Robert I., Gleeson, Michelle L., Mikhael, Joseph, Danese, Mark D.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Hindawi Publishing Corporation 2012
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3434403/
https://ncbi.nlm.nih.gov/pubmed/22969803
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2012/978391
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia